These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 33666822)

  • 1. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B; Grams ME; Chang A; Inker LA; Coresh J; Shin JI
    Am J Cardiol; 2022 Feb; 165():124-130. PubMed ID: 34937658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
    Lin DS; Lee JK; Hung CS; Chen WJ
    Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.
    Carretero Gómez J; Arévalo Lorido JC; Gómez Huelgas R; García de Lucas D; Mateos Polo L; Varela Aguilar JM; Seguí Ripoll JM; Ena J;
    Can J Diabetes; 2019 Apr; 43(3):186-192. PubMed ID: 30415909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
    Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
    J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
    [No Abstract]   [Full Text] [Related]  

  • 11. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China.
    Li C; Guo S; Huo J; Gao Y; Yan Y; Zhao Z
    Front Endocrinol (Lausanne); 2022; 13():987081. PubMed ID: 36277697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors.
    Liu J; Su X; Hao Y; Liu J;
    Sci Rep; 2024 Aug; 14(1):18290. PubMed ID: 39112571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
    de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO
    Diabetes Obes Metab; 2024 Jul; 26(7):2787-2795. PubMed ID: 38618983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
    Edwards K; Li X; Lingvay I
    J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.
    Dave CV; Schneeweiss S; Wexler DJ; Brill G; Patorno E
    Diabetes Care; 2020 Apr; 43(4):921-924. PubMed ID: 32041899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
    Tang EHM; Wong CKH; Lau KTK; Fei Y; Cheung BMY
    Diabetes Res Clin Pract; 2021 Oct; 180():109071. PubMed ID: 34592391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Prescriptions of Cardioprotective Diabetic Agents After Coronary Artery Bypass Grafting Among U.S. Veterans.
    Deo SV; McAllister DA; Al-Kindi S; Elgudin Y; Chu D; Pell J; Sattar N
    Diabetes Care; 2022 Dec; 45(12):3054-3057. PubMed ID: 36256925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.